| |
 |
 |
 |
 |
 |
 |
 |
June 7, 2004
AnGes MG
Forms a Business Alliance with NeoChemir.
Expands treatments of ischemic diseases through introduction
of a new carbon dioxide generating wound dressing material |
 |
|
|
AnGes MG at this time would like to officially
announce its signing of an exclusive licensing agreement for
the Japanese market with NeoChemir Inc. (hereinafter "NeoChemir")
to distribute their new carbon dioxide generating wound dressing,
whose patent is filed by NeoChemir.
AnGes MG is currently using hepatocyte growth factor (HGF) in
its clinical research to develop a new arterialization therapy
intended for use in the future treatment of ischemic diseases
such as arteriosclerosis obliterans (ASO). One target under development
is a new type of treatment for the patients with ischemic skin
ulcers. The introduction at this time of this new wound dressing
for the treatment of ischemic ulcers and other diseases is expected
to reinforce our product lineup, and help us continue to address
the needs of the medical industry in the field of ischemic diseases.
Up to now it has been considered that the most appropriate therapy
for an ischemic ulcer wound was to cover the affected area with
gauze to let dry and form a scab. It has been learned in recent
years, however, that the most desirable cure for such wounds
is to maintain them in a moderately moist environment without
letting the affected areas dry up. The wound heals more quickly
due to a growth promoting substance secreted in the liquid exuded
by the wound, giving rise to what is known as wet healing. This
finding has led to redesigned wound dressings so that a strong
moisturizing effect is added to its protective properties.
The wound coating material developed by NeoChemir which we plan
to introduce at this time is characterized by its generation
of carbon dioxide gas, which in addition to the aforementioned
strong moisturizing action, increases oxygen concentration and
blood flow in the tissue. This wound dressing is composed of
two layers of different materials which when placed in contact
with each other generate carbon dioxide, and then changes into
a material with strong moisturizing properties.
At AnGes MG, we expect that this carbon dioxide generating wound
dressing can also be used for to treat ulcers for which conventional
dressings are found ineffective, because it is expected to demonstrate
much stronger curative effects than possible up to the present.
In addition to ischemic skin ulcers, we plan to work on this
new wound dressing to broaden its application to a wider range
of skin wounds, including bedsores. This plan is based on the
increasing numbers of patients suffering from bedsores expected
in the near future due to the rapid aging of society.
AnGes MG plans to immediately launch a research and development
project on this new wound dressing material with the objective
of developing a new medical products, to be marketed two years
or more in the future . |
| Company
Profile |
|
|
|
| NeoChemir Inc. |
| Headquarters: |
2-20, Gokodori 4-Chome, Chuo-ku, Kobe 651-0087, JAPAN |
| President: |
Masaya Tanaka |
| Establishment: |
May, 2001 |
| Capital: |
92 million yen (as of May, 2004) |
| Personnel: |
7 (as of May, 2004) |
| Business Field: |
Research and development, etc. of pharmaceutical products,
medical devices, cosmetics, etc. |
| AnGes MG, Inc. |
| Headquarters: |
1-4-2 Shinsenri Higashi-machi, Toyonaka City, Osaka |
| President: |
Ei Yamada |
| Establishment: |
December, 1999 |
| Capital: |
4,784 million yen (as of December, 2003) |
| Personnel: |
51 (as of December, 2003) |
| Sales: |
2,452 million yen (for the term ended in December,
2003) |
| Business Field: |
Research and development of genetic medication |
|
|
|
